These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pharmaceutical biotechnology products approved within the European Union. Walsh G Eur J Pharm Biopharm; 2003 Jan; 55(1):3-10. PubMed ID: 12551698 [TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody: the corner stone of modern biotherapeutics. Xia ZN; Cai XT; Cao P Yao Xue Xue Bao; 2012 Oct; 47(10):1275-80. PubMed ID: 23289138 [TBL] [Abstract][Full Text] [Related]
5. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. Beck A; Reichert JM MAbs; 2013; 5(5):621-3. PubMed ID: 23924791 [TBL] [Abstract][Full Text] [Related]
8. Fresh from the biotech pipeline-2018. Morrison C Nat Biotechnol; 2019 Feb; 37(2):118-123. PubMed ID: 30718867 [No Abstract] [Full Text] [Related]
9. First biosimilar drug approved for sale in the United States. Hede K J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26142444 [No Abstract] [Full Text] [Related]
10. Growing pains for biopharmaceuticals. Ashton G Nat Biotechnol; 2001 Apr; 19(4):307-11. PubMed ID: 11283578 [No Abstract] [Full Text] [Related]
11. 10 years of biosimilars: lessons and trends. Royzman I; Shah K Nat Rev Drug Discov; 2020 Jun; 19(6):375. PubMed ID: 32358591 [No Abstract] [Full Text] [Related]
12. Monoclonal antibody successes in the clinic. Reichert JM; Rosensweig CJ; Faden LB; Dewitz MC Nat Biotechnol; 2005 Sep; 23(9):1073-8. PubMed ID: 16151394 [TBL] [Abstract][Full Text] [Related]
17. Barriers to biosimilar utilization in the United States. Dalpoas SE; Socal M; Proctor C; Shermock KM Am J Health Syst Pharm; 2020 Nov; 77(23):2006-2014. PubMed ID: 33091103 [No Abstract] [Full Text] [Related]
18. The Biosimilar Pipeline Seams Seem To Be Bursting. Reinke T Manag Care; 2017 Mar; 26(3):24-25. PubMed ID: 28510516 [TBL] [Abstract][Full Text] [Related]